LONN logo

Lonza Group AG Stock Price

SWX:LONN Community·CHF 38.9b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 33 Fair Values set on narratives written by author

LONN Share Price Performance

CHF 553.60
10.60 (1.95%)
18.1% undervalued intrinsic discount
CHF 676.18
Fair Value
CHF 553.60
10.60 (1.95%)
18.1% undervalued intrinsic discount
CHF 676.18
Fair Value
Price CHF 553.60
AnalystConsensusTarget CHF 676.18

LONN Community Narratives

AnalystConsensusTarget·
Fair Value CHF 676.18 18.1% undervalued intrinsic discount

Vacaville And Visp Facilities Will Secure Future Biologics Demand

0users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
CHF 676.18
18.1% undervalued intrinsic discount
Revenue growth
11.39% p.a.
Profit Margin
16.79%
Future PE
31.82x
Share price in 2028
CHF 765.87

Snowflake Analysis

Reasonable growth potential with proven track record.

2 Risks
3 Rewards

Lonza Group AG Key Details

CHF 7.1b

Revenue

CHF 4.5b

Cost of Revenue

CHF 2.6b

Gross Profit

CHF 1.9b

Other Expenses

CHF 733.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
10.44
36.47%
10.33%
53.2%
View Full Analysis

About LONN

Founded
1897
Employees
19299
CEO
Wolfgang Wienand
WebsiteView website
www.lonza.com

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. Its Small Molecules segment provides integrated development and manufacturing services for small molecule drug substances and their intermediates. This segment also supports customers across aspects of design, development, and manufacturing, such as particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. Its Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Recent LONN News & Updates

What Is Lonza Group AG's (VTX:LONN) Share Price Doing?

Sep 10
What Is Lonza Group AG's (VTX:LONN) Share Price Doing?

Recent updates

No updates